Gilead Sciences, Inc. $GILD is Kerusso Capital Management LLC's 6th Largest Position

Key Points

• Kerusso Capital increased its stake in Gilead by 31.3% in Q4 to 43,720 shares (worth $5.37M), making GILD its 6th largest holding and representing about 2.5% of the firm's portfolio.
• Gilead beat quarterly EPS and revenue expectations, set FY2026 guidance of 8.45–8.85 EPS, raised its quarterly dividend to $0.82 ($3.28 annual, 2.5% yield), and enjoys a market view of "Moderate Buy" with an average analyst target of $157.35 after several recent price-target upgrades.

Kerusso Capital Management LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,720 shares of the biopharmaceutical company's stock after acquiring an additional 10,421 shares during the quarter. Gilead Sciences accounts for approximately 2.5% of Kerusso Capital Management LLC's holdings, making the stock its 6th largest position. Kerusso Capital Management LLC's holdings in Gilead Sciences were worth $5,366,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the third quarter valued at $26,000. Financial Consulate Inc. increased its holdings in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 109 shares in the last quarter. MTM Investment Management LLC raised its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 176 shares during the last quarter. BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the 4th quarter worth about $31,000. Finally, Millstone Evans Group LLC lifted its stake in Gilead Sciences by 58.7% during the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 118 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent analyst reports. Scotiabank raised their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. Citigroup increased their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $160.00 target price on shares of Gilead Sciences in a research report on Wednesday, February 11th. Finally, Truist Financial increased their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $157.35.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $133.64 on Friday. The firm's 50 day moving average price is $142.93 and its 200-day moving average price is $131.90. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock has a market capitalization of $165.88 billion, a PE ratio of 19.74, a price-to-earnings-growth ratio of 1.76 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter last year, the firm posted $1.90 earnings per share. The firm's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 8.63 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's dividend payout ratio is 48.45%.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. This represents a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 178,640 shares of company stock valued at $26,691,550 in the last 90 days. Company insiders own 0.30% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.